Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of March, 2020

 

Commission File Number: 001-37353

 

BIONDVAX PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

 

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jeusalem, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

On March 24, 2020, BiondVax Pharmaceuticals Ltd. issued a press release announcing new directors elected to BiondVax’s Board of Directors.

A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press Release dated March 24, 2020

 

Exhibits 99.1 of this Report on Form 6-K are hereby incorporated by reference into the Company's Registration Statement on Form F-3 (Registration No. 333-201283). 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BiondVax Pharmaceuticals Ltd.
Date: March 24, 2020	By:	/s/ Ron Babecoff
		Ron Babecoff
		Chief Executive Officer

 

 

2